Drug Profile
Y-pegylated recombinant interferon alpha-2a - Amoytop Biotech/BioGeneric Pharma
Alternative Names: YPEG-rhIFNα-2a - Amoytop Biotech/BioGeneric PharmaLatest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator Amoytop Biotech; BioGeneric Pharma
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Immunostimulants; Interferon alfa 2a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C
Most Recent Events
- 11 Oct 2021 No development reported - Phase-II/III for Hepatitis C (Combination therapy, Treatment-naive) in Egypt (SC)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-B in China (SC, Irrigation)
- 01 Nov 2010 Clinical trials in Hepatitis B in China (SC)